Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | PKM | P14618 | 1/20 | 0.55 |
| ▸ | UTS2R | Q9UKP6 | 2/20 | 0.45 |
| ▸ | JAK2 | O60674 | 1/20 | 0.44 |
| ▸ | JAK1 | P23458 | 1/20 | 0.44 |
| ▸ | TYK2 | P29597 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 6/20 | 0.44 |
| ▸ | LMNA | P02545 | 6/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | GNRHR | P30968 | 1/20 | 0.41 |
| ▸ | HTR4 | Q13639 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19639670 | 0.86 | L3MBTL1 (0.47) | KDM4ELMNAMEN1KMT2A | |
| SCHEMBL17753688 | 0.76 | KDM4E (0.55) | KDM4EPKMUTS2RJAK2JAK1 | |
| SCHEMBL19639663 | 0.75 | KDM4E (0.46) | KDM4EPKMUTS2RJAK2JAK1 | |
| SCHEMBL17796229 | 0.72 | KDM4E (0.72) | KDM4EPKMUTS2RTP53LMNA | |
| SCHEMBL26131403 | 0.72 | KDM4E (1.00) | KDM4EPKMTP53KMT2A | |
| SCHEMBL17753908 | 0.71 | TAF1 (0.52) | KDM4EPKMUTS2RJAK2JAK1 | |
| SCHEMBL13947430 | 0.71 | KDM4E (0.80) | KDM4EPKMTP53LMNAMEN1 | |
| SCHEMBL15661860 | 0.71 | KDM4E (0.80) | KDM4EPKMLMNAMEN1KMT2A | |
| SCHEMBL3036555 | 0.71 | KDM4E (0.80) | KDM4EPKMUTS2RMEN1KMT2A | |
| SCHEMBL14331908 | 0.70 | KDM4E (0.62) | KDM4EPKMJAK2JAK1TYK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10258603-B2 | Therapeutic compounds and uses thereof | GENENTECH, INC. (US) | 2019-04-16 | — | — | US | disclosed |
| US-20170340604-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2017-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10258603-B2 | Therapeutic compounds and uses thereof | BRD4, BRDT, BRD3 | KDM4E 320/4885PKM 3411/4885UTS2R 681/4885 |
| US-20170340604-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | BRD4, BRDT, BRD3 | KDM4E 320/4885PKM 3411/4885UTS2R 681/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.